In today’s session Allergan plc Ordinary Shares (AGN) recorded an unusually high (2,287) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious AGN decrease. With 2,287 contracts traded and 25544 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: AGN161021P00245000 closed last at: $13.2 or 10.8% down. About 1.77 million shares traded hands. Allergan plc Ordinary Shares (NYSE:AGN) has declined 22.34% since March 14, 2016 and is downtrending. It has underperformed by 27.96% the S&P500.
Analysts await Allergan plc Ordinary Shares (NYSE:AGN) to report earnings on November, 2. They expect $3.56 earnings per share, up 2.30% or $0.08 from last year’s $3.48 per share. AGN’s profit will be $1.43B for 15.79 P/E if the $3.56 EPS becomes a reality. After $3.35 actual earnings per share reported by Allergan plc Ordinary Shares for the previous quarter, Wall Street now forecasts 6.27% EPS growth.
Allergan plc Ordinary Shares (NYSE:AGN) Ratings Coverage
Out of 16 analysts covering Allergan Inc. (NYSE:AGN), 13 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 81% are positive. Allergan Inc. has been the topic of 41 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Tuesday, November 24 by Mizuho. Mizuho maintained Allergan plc Ordinary Shares (NYSE:AGN) on Friday, May 13 with “Neutral” rating. The stock of Allergan plc Ordinary Shares (NYSE:AGN) earned “Buy” rating by Deutsche Bank on Tuesday, August 9. Leerink Swann maintained Allergan plc Ordinary Shares (NYSE:AGN) rating on Wednesday, October 28. Leerink Swann has “Outperform” rating and $342.0 price target. The firm has “Buy” rating by Deutsche Bank given on Thursday, April 7. Leerink Swann maintained the shares of AGN in a report on Tuesday, July 28 with “Outperform” rating. The rating was maintained by Deutsche Bank with “Buy” on Friday, August 7. The rating was initiated by Guggenheim with “Neutral” on Monday, April 18. The stock has “Outperform” rating given by Wells Fargo on Friday, February 19. The firm has “Buy” rating by S&P Research given on Friday, October 30.
According to Zacks Investment Research, “Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 0.46 in 2016 Q2. Its down 0.29, from 0.75 in 2016Q1. The ratio dropped, as 11 funds sold all Allergan plc Ordinary Shares shares owned while 2 reduced positions. 3 funds bought stakes while 3 increased positions. They now own 58,328 shares or 8.83% less from 63,978 shares in 2016Q1.
Mitchell Mcleod Pugh And Williams accumulated 0.83% or 3,975 shares. Frontier Inv Mgmt Company holds 0.94% of its portfolio in Allergan plc Ordinary Shares (NYSE:AGN) for 32,758 shares. American Research And Mngmt accumulated 33 shares or 0% of the stock. Dowling And Yahnke Lc owns 2,145 shares or 0.06% of their US portfolio. Grassi Inv has 0.22% invested in the company for 5,125 shares. Mengis Cap Management holds 6,210 shares or 1.27% of its portfolio. Gemmer Asset Mgmt Ltd Liability Company, a California-based fund reported 127 shares. Connors Investor accumulated 1,000 shares or 0.04% of the stock. Moreover, Chartist Ca has 0% invested in Allergan plc Ordinary Shares (NYSE:AGN) for 1,844 shares. Marshwinds Advisory Com last reported 927 shares in the company. Bartlett & Limited Liability last reported 494 shares in the company. Armstrong Henry H Associate, a Pennsylvania-based fund reported 3,690 shares.
AGN Company Profile
Allergan plc, incorporated on May 16, 2013, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacturing, marketing and distribution of pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company’s divisions are US Brands, US Medical Aesthetics and International Brands. The US Brands segment includes sales and expenses relating to branded products within the United States, including certain Botox therapies. The US Medical Aesthetics segment includes sales and expenses relating to aesthetics and dermatology products within the United States, including certain Botox therapies. The International Brands segment includes sales and expenses relating to products sold outside of the United States. The Firm has global rights to RST-001, a gene therapy approach for the potential treatment of retinitis pigmentosa (RP). The RST-001 optogenetic approach includes a photosensitivity gene, channelrhodopsin-2, to create new photosensors in retinal ganglion cells to restore vision in retinal degenerative conditions. The RST-001 is in Phase I/IIa clinical trials. It has global rights to AKN-083, a preclinical farnesoid X receptor (FXR) agonist for the treatment of non-alcoholic steatohepatitis (NASH).
More news for Allergan plc Ordinary Shares (NYSE:AGN) were recently published by: Investorplace.com, which released: “Allergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars?” on September 20, 2016. Valuewalk.com‘s article titled: “Allergan plc Ordinary Shares (AGN) Collapses On Treasury Ruling, Analysts React” and published on April 05, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.